淋巴细胞激活基因-3在头颈部肿瘤免疫治疗的研究进展

近年来头颈部肿瘤的免疫治疗在临床试验和实践中获得了令人满意的疗效。淋巴细胞激活基因-3(LAG-3)是一类重要的共抑制分子,与其他分子协同参与对人体免疫系统的负性调控作用。因此,LAG-3有望成为头颈部肿瘤新的免疫治疗靶点,同时LAG-3和PD-1的联合免疫治疗也展现出了巨大的治疗前景。本文就LAG-3的基因定位和结构、表达与配体结合、生物学功能、在头颈部肿瘤中的作用及相关免疫治疗方法进行综述。

Research progress in the anti-LAG-3 immunotherapy of head and neck carcinoma

Recently, the immunotherapy of head and neck tumors has achieved satisfactory results in clinical trials and practice. Lymphocyte activating gene-3 (LAG-3) is an important co-inhibitory molecule which participates in the negative regulation of the human immune system together with other molecules. LAG-3 is expected to become a new target of immunotherapy for head and neck cancer. At the same time, the combination of LAG-3 and PD-1 immunotherapy also shows great prospects for the treatment. This article reviews the LAG-3’s gene localization and structure, expression and ligand binding, biological function, the role of LAG-3 in head and neck tumors and the related immunotherapy.